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Abstract Taking parameter uncertainty into account is key
to make drug development decisions such as testing whether
trial endpoints meet defined criteria. Currently usedmethods
for assessing parameter uncertainty in NLMEM have limi-
tations, and there is a lack of diagnostics for when these
limitations occur. In this work, a method based on sampling
importance resampling (SIR) is proposed, which has the
advantage of being free of distributional assumptions and
does not require repeated parameter estimation. To perform
SIR, a high number of parameter vectors are simulated from
a given proposal uncertainty distribution. Their likelihood
given the true uncertainty is then approximated by the ratio
between the likelihood of the data given each vector and the
likelihood of each vector given the proposal distribution,
called the importance ratio. Non-parametric uncertainty
distributions are obtained by resampling parameter vectors
according to probabilities proportional to their importance
ratios. Two simulation examples and three real data exam-
ples were used to define how SIR should be performed with
NLMEM and to investigate the performance of the method.
The simulation examples showed that SIR was able to
recover the true parameter uncertainty. The real data exam-
ples showed that parameter 95 % confidence intervals (CI)
obtained with SIR, the covariance matrix, bootstrap and log-
likelihood profiling were generally in agreement when 95 %
CI were symmetric. For parameters showing asymmetric
95 % CI, SIR 95 % CI provided a close agreement with log-
likelihood profiling but often differed from bootstrap 95 %
CI which had been shown to be suboptimal for the chosen
examples. This work also provides guidance towards the SIR
workflow, i.e.,which proposal distribution to choose and how
many parameter vectors to sample when performing SIR,
using diagnostics developed for this purpose. SIR is a
promising approach for assessing parameter uncertainty as it
is applicable in many situations where other methods for
assessing parameter uncertainty fail, such as in the presence
of small datasets, highly nonlinear models or meta-analysis.
Keywords Sampling importance resampling  Parameter
uncertainty  Confidence intervals  Asymptotic covariance
matrix  Nonlinear mixed-effects models  Bootstrap
Introduction
Nonlinear mixed effects models (NLMEM) are increas-
ingly used to support drug development [1]. Even though
NLMEM have been mainly employed for exploratory
purposes, they have been advocated as powerful tools also
in confirmatory settings [2]. In such settings, the adequacy
of the structural and distributional assumptions inherent to
NLMEM is particularly important in order to draw correct
conclusions. One of the aspects requiring scrutiny is
parameter uncertainty. Indeed, parameter uncertainty is key
to make drug development decisions such as testing whe-
ther trial endpoints meet defined criteria, calculating the
power of a prospected trial [3], taking a go/no go decision
at an interim analysis [4], selecting doses for a Phase II trial
[5], or optimizing dosing regimen [6]. Parameter uncer-
tainty in NLMEM is usually obtained from the asymptotic
covariance matrix at the maximum likelihood parameter
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estimates assuming a multivariate normal distribution,
from a parametric or nonparametric bootstrap procedure, or
less commonly from log-likelihood profiling.
Using the covariance matrix, model parameters are
assumed to be normally distributed and their confidence
intervals (CI) are computed from the standard errors
obtained based on the inverse of the observed Fisher
information matrix [7]. However, when the settings are far
from asymptotic conditions (i.e., when the number of
observations and/or individuals is low) or when models
display substantial nonlinearity, the assumption of nor-
mality may not hold. Reparameterization, for example
using exponentiated parameters, has been advocated as an
approach to address non-normal uncertainty [8]. However,
the adequacy of the new distribution is by no means
guaranteed. Determining whether the covariance matrix is
appropriate, i.e., quantifying the distance from asymptotic
conditions or the degrees of nonlinearity, is not straight-
forward. Measures of nonlinearity have been proposed [9]
but they are controversial [10] and have not been applied to
NLMEM. In addition, numerical issues may hamper the
computation of the inverse of the FIM [11] and prevent its
use.
The bootstrap [12] enables parametric or nonparametric
parameter CI to be computed from a given number of
parameter vectors which are estimated based on boot-
strapped datasets. Nonparametric case bootstrap methods,
where no assumption about uncertainty distribution is
made, are the most commonly used in NLMEM. In non-
parametric case bootstrap, new datasets are computed by
resampling with replacement individual data from the
original dataset. The new datasets are of the same size as
the original dataset, but differ in the included individuals.
The authors refer to Thai et al. [13] for a comparison of the
performance of different bootstrap methods in NLMEM.
Usage of the bootstrap may be limited due to time as it
requires a high number of potentially computationally
intensive estimation steps, even though some efforts have
been made to reduce this [14]. A further limitation is that it
is not applicable when data from only few individuals is
available, when frequentist priors are used (a parameter for
which uncertainty is high because of uninformative data
would appear precise as all of its bootstrapped values
would stay close to its prior value) or when doing model-
based meta-analysis (different studies are typically not
exchangeable). There is also a lack of consensus about both
the handling of bootstrapped samples for which the esti-
mation was not successful, and about which method to use
to compute bootstrap CI. Just as for the covariance matrix,
it is difficult to judge in which situations the use of boot-
strap is appropriate. Recent work suggests that datasets
commonly used in NLMEM are actually too small for the
bootstrap to be properly applied [13, 15].
Log-likelihood profiling [16, 17] can also be used to
assess parameter uncertainty. Like the bootstrap, this
method makes no assumption about uncertainty distribu-
tion. Parameter CI are computed in a univariate manner by
estimating the objective function value (OFV), which
corresponds to minus two times the log-likelihood up to a
constant, at an array of fixed values of the parameter of
interest while the other parameters are estimated. Values
which lead to differences in OFV (dOFVs, calculated as the
OFV at a given array of parameter estimates minus the
OFV at the maximum likelihood estimates) equal to the
value of the Chi square distribution for one degree of
freedom and at the a confidence level are taken as the outer
bounds of the 1 - a % CI. Minimization problems and
long runtimes can be an issue, even if the number of
estimations needed is typically much lower than with the
bootstrap. The main drawback of log-likelihood profiling is
that it does not provide full uncertainty distributions. Only
the bounds of a parameter’s CI are available, and despite
some work on multivariate implementation [18], as of now
it cannot be used to generate entire sets of parameters.
All currently available methods for assessing parameter
uncertainty thus present non negligible drawbacks in
NLMEM settings. Sampling importance resampling (SIR),
an alternative method making no distributional assump-
tions on uncertainty and devoid of repeated estimation
steps, could address some of these shortcomings.
The SIR algorithm has been proposed by Rubin [19] to
obtain posterior parameter uncertainty distributions. SIR
was developed in the Bayesian setting as a noniterative and
universally applicable method for obtaining draws from an
unknown distribution based on draws from an approxi-
mation of this distribution. The draws are resampled based
on their importance ratios, which measure the agreement
between the approximated distribution and the data at
hand, and are expected to be proportional to the resampling
probabilities given the unknown distribution. Starting from
any proposal distribution, SIR will thus resample a set of
samples representative of the unknown distribution. In the
past, SIR has been used to calculate marginal densities
[20], to impute missing data [21] and in Bayesian mod-
elling [22, 23]. It has been applied in the healthcare domain
to project trends in HIV/AIDS epidemics [24], to estimate
cost-effectiveness [25] and to perform optimal experi-
mental design in systems pharmacology [26]. However, to
the authors’ knowledge the application of SIR to estimate
parameter uncertainty distributions in NLMEM has not
previously been described in the literature.
The aim of this work was to develop a workflow for
performing SIR in the context of NLMEM, and to apply
this workflow to compare parameter uncertainty obtained
with SIR to parameter uncertainty obtained with commonly
used methods.
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Methods
SIR algorithm and implementation in NLMEM
The objective of SIR is to provide, for a given model and a
given set of data, a set of m parameter vectors which are
representative of the true and unknown parameter uncer-
tainty distribution. SIR is performed in the following three
steps:
(1) Step 1 (sampling): M (M[m) parameter vectors are
randomly sampled from a proposal distribution.
(2) Step 2 (importance weighting): For each of the
M sampled parameter vectors, an importance ratio is
computed. This importance ratio corresponds to the
probability of being sampled in the true parameter
uncertainty distribution. It is computed as the
likelihood of the data given the parameter vector,
weighted by the likelihood of the parameter vector in








where IR is the importance ratio, dOFV is the difference
between the objective function value (OFV) of the
parameter vector and the OFV of the final parameter esti-
mates on the original data, and relPDF is the value of
the probability density function of the parameter vector
relative to the probability density of the final parameter
estimates.
(3) Step 3 (resampling): In the last step, m parameter
vectors are resampled from the pool of M simulated
vectors based on their importance ratio. These
vectors can be used to compute desired CI.
A summary of the SIR procedure is provided in Fig. 1.
Full details on the SIR rationale and implementation are
provided in Online Resource 1.
SIR workflow
In theory, SIR results should be independent on the chosen
SIR settings, which are the proposal distribution and the
number of samples M. However this is not always the case,
for example if the proposal is very far from the true dis-
tribution and the number of samples is too low. In this
work, settings which would be in general appropriate for
NLMEM were explored, and diagnostics to judge a pos-
teriori whether SIR settings should be improved were
developed.
SIR was initially proposed to be performed based on a
default workflow, where the estimated ‘‘sandwich’’ vari-
ance–covariance matrix, which is a function of the Hessian
and the cross-product gradient, was used as proposal dis-
tribution. The number of samples M was set to 5000 and
the number of resamples m was set to 1000.
Potential improvements of this workflow were then
investigated. First, different numbers of samples were
investigated (M = 2000, 4000, 6000, 8000 and 10,000).
The number of resamples m was not modified, as this
number was chosen in order to have sufficient precision on
the outer bounds of the CI of interest, which was the 95 %
CI. Note that m can be chosen freely depending on the
desired precision of the uncertainty. What is important for
SIR is thus not so much the intrinsic value of M, but rather
its relation to m, expressed as M/m ratios (M/m = 2, 4, 6, 8
and 10). One should choose m in the same manner as the
number of samples in a bootstrap, i.e., depending on the
intended use. For example, m = 1000 would be recom-
mended to compute a 95 % CI. M would then derived from
the recommended M/m ratio, 5 by default, to be 5000.
Secondly, different proposal distributions were investi-
gated. They corresponded to inflations and deflations of the
covariance matrix, for which all variances and covariances
of the uncertainty distribution were either increased or
decreased by a certain factor (0.5, 0.75 1.5 and 2). It is very
important to note that proposal distributions not based on
the covariance matrix can also be used, especially if the
covariance matrix is not estimable. This is a major
advantage of SIR which will be further detailed in the
discussion. Lastly, performing SIR using resampling with
replacement in order to increase SIR efficiency was also
investigated. Because replacement was not recommended,
results from this investigation are not discussed here, but
they are provided in Online Resource 2.
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Fig. 1 The three steps of the SIR procedure
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Application of SIR to simulated examples and real
data examples
SIR was used to obtain parameter uncertainty of two
simulation examples and three real data examples. For the
real data examples, 95 % CI of model parameters were
compared to the CI obtained from the covariance matrix,
bootstrap (1000 samples, no stratification) and log-likeli-
hood profiling. For the simulation examples, 95 % CI were
also computed and used to calculate the proportion of
datasets for which the computed CI included the true
simulation value, a metric known as coverage. The cov-
erage obtained with SIR was compared to the coverage
obtained with the covariance matrix. As uncertainty
depends on the estimation method, all comparisons should
be done using the same method. The first order conditional
estimation with interaction method was used in this work.
The three real data examples were moxonidine [27],
pefloxacin [28] and phenobarbital [29]. Models were
multiple dose pharmacokinetic (PK) 1-compartment mod-
els with oral or intravenous (i.v.) administration. Data
ranged from rich to sparse. The simulation models com-
prised an i.v. 1-compartment PK model with first-order
elimination and a pharmacodynamic (PD) dose–response
Emax model. Simulated datasets comprised 20, 50 or 200
individuals, each providing four observations. For each
model and dataset size, 500 simulations and re-estimations
were performed. Details on model structures, parameters
and designs are available in Online Resource 3.
SIR diagnostics
When performing SIR, the user needs to choose a proposal
distribution and a samples/resamples ratio M/m. Diagnos-
tics were developed to judge whether the chosen SIR set-
tings were appropriate, i.e., whether SIR results could be
considered final. Three graphical diagnostics were devel-
oped: (1) the dOFV distribution (first proposed in [15] in
connection with bootstrap), which is a global diagnostic
assessing the adequacy of both the proposal distribution
and M/m for all parameters simultaneously (2) the spatial
trends plot, which is a local diagnostic assessing the ade-
quacy of the proposal distribution separately for each
parameter and (3) the temporal trends plot, which is a local
diagnostic assessing the adequacy of M/m separately for
each parameter. An illustration of the diagnostics is
available in Fig. 2. The diagnostics should be used as
follows: SIR settings are considered adequate if the dOFV
distribution after SIR is at or below the Chi square distri-
bution and no trends are apparent in the temporal trends
plot. The investigations on the SIR workflow will provide
guidance towards what to do when this is not the case.
dOFV distribution plot (left panel, Fig. 2)
dOFV quantile distributions were suggested as a method to
diagnose the appropriateness of bootstrap uncertainty dis-
tributions [15] andwere applied to SIR. The principle behind
this diagnostic is that if the parameter vectors resampled by
SIR were the true uncertainty, the difference between their
OFV and the OFV obtained at the final parameter estimates
of the model should follow a Chi square distribution. The
degrees of freedom (df) of this distribution is equal to the
number of estimated parameters for an unconstrained fixed
effects model [30], but the exact df is unknown for NLMEM.
Indeed, it is expected to be equal to or below the number of
estimated parameters, notably due to the estimation of ran-
dom effects and other bounded parameters, which may not
account for full degrees of freedom [31]. Plotting the dOFV
distributions obtained from theM proposal samples and from
the m SIR resamples against a Chi square distribution with
degrees of freedom equal to the number of estimated
parameters informs about the adequacy of the proposal dis-
tribution and M/m. If the dOFV distribution obtained from
theM samples is at or close to the Chi square distribution, it
means that the proposal distribution is close to the true dis-
tribution; if it is far above or below, it means that it is quite
different from the true distribution. If the dOFV distribution
obtained from the m SIR resamples is at or below the Chi
square distribution, M/m may have been sufficient and
should be further investigated with the temporal trends plot;
if the distribution is above the Chi square distribution, M/m
was not sufficient. Themean of the dOFV distribution can be
used to quantitatively compare the distributions; it corre-
sponds to the degrees of freedom if the distribution is a Chi
square distribution.
Spatial trends plot (middle panel, Fig. 2)
This plot enables to visualize, parameter by parameter,
whether the proposal distribution differs from the true
uncertainty. The spatial trends plot shows the resampling
proportion, i.e., the number of resampled parameters divi-
ded by the number of parameters available from the
M samples (on the y-axis), in different regions, or bins, of
the parameter space (on the x-axis). The parameter space is
defined as all values comprised between the lowest sam-
pled parameter value and the highest sampled parameter
value, and is divided into ten bins which all contain an
equal number of samples. Four types of trends can be
observed in this plot:
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– Horizontal trend (i.e., no trend): If the observed
resampling proportion is within stochastic noise around
the expected proportion for all bins, it means that the
proposal distribution is close to the true uncertainty.
– Bell-shaped trend: If the observed proportion is higher
in the center and lower at the ends, it means that
parameters close to the final estimates are resampled
more often than those further away from them, and thus
that the proposal distribution is wider than the true
distribution.
– u-shaped trend: Oppositely, if the observed proportion
is lower in the center and higher at the ends, it means
that the proposal distribution is narrower than the true
distribution.
– Diagonal trend: If the proportion is higher at one end
and lower at the other, it means that the proposal
distribution has a different (a)symmetry than the true
distribution.
The spatial trends plot indicates how the proposal differs
from the true distribution, but it does not inform whether
SIR was able to compensate for these differences.
Temporal trends plot (right panel, Fig. 2)
This plot indicates, parameter by parameter, whether M/m
was high enough to compensate for the differences
between the proposal distribution and the true uncertainty.
SIR can succeed as long as there are enough ‘‘good’’
samples available in the proposal distribution. The limiting
factor for this is the bin that shows the highest proportion
of resamples in the spatial trends plot. This bin, referred to
as the top spatial bin, is the region of the parameter space
where SIR is most likely to run out of ‘‘good’’ samples if
M/m is not sufficient. Instead of binning sampled parame-
ters based on their value as for the spatial trends plot,
resampled parameters are now binned based on the order in
which they were resampled: the parameters that were
resampled first (i.e., most likely those with the highest
importance ratios) belong to the first ‘‘time bin’’, and those
that were resampled last belong to the last bin. The tem-
poral trends plot then shows, for each of the 5 time bins (on
the x-axis), the number of resamples that belongs to the top
spatial bin (on the y-axis) together with the sampling noise.
Two trends can be observed for this diagnostic:
– Horizontal trend (i.e., no trend): If the number of
resampled parameters in the top spatial bin is within
sampling noise for all time bins, M/m was sufficient to
compensate for potential differences between the
proposal distribution and the true uncertainty.
– Downward diagonal trend: If on the other hand the
number of resampled parameters decreases over time, it
indicates a depletion of samples in the top bin and that
there were not enough good samples in the SIR
procedure to fully correct the proposal uncertainty:
M/m was not sufficient.
Software
NONMEM 7.2 and 7.3 [32] aided by PsN 3.5.9 and above
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Temporal trends plot: exhaustion of samples
Fig. 2 Diagnostic plots for the moxonidine real data example
showing that SIR settings were appropriate. The SIR dOFV distri-
bution is below the Chi square distribution in the dOFV distribution
plot (left panel). Diagonal upward and bell-shaped trends in the
spatial trends plot (middle panel) indicate that the proposal distribu-
tion is different from the true uncertainty. Horizontal trends in the
temporal trends plot (right panel) show that the M/m ratio was high
enough for SIR to compensate the inadequacy of the proposal
distribution. See text in the ‘‘Methods’’ section and additional legends
in Online Resource 4 for further details. (CL clearance, V volume, KA
absorption rate, TLAG lag-time, IIV inter-individual variability, IOV
inter-occasion variability, RUV residual unexplained variability)
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computation. RStudio 0.98 using R 3.1.2 [33] was used for
SIR computation and graphical output.
Results
SIR was implemented as a modelling supporting tool in the
PsN software and is thoroughly documented in the PsN
user guide. It is fully automated and enables the user to
easily perform SIR with any NONMEM-based model,
providing numerical summary results such as relative
standard errors (RSE) and CI as well as extensive graphical
diagnostics.
Real data examples: SIR diagnostics
and comparative parameter CI 95 %
SIR settings with the default workflow proved appropriate
based on the developed diagnostics for the three real data
examples. In all examples, the uncertainty given by the
covariance matrix appeared different from the true distri-
bution, as evidenced by dOFV distributions above the Chi
square distribution and non-horizontal trends in the spatial
trends plots. A M/m ratio of 5 was sufficient to compensate
the inadequacy in all examples: the dOFV distributions of
the SIR resamples were below the Chi square distribution
and the temporal trends plots displayed no trends.
For the moxonidine example (Fig. 2), the dOFV distri-
bution of the proposal was well above the Chi square
distribution (df 26.4 vs. 11), indicating that the asymptotic
covariance matrix was relatively far from the true uncer-
tainty. This was confirmed by the spatial trends plot, which
showed bell-shaped trends for lag-time (TLAG), absorp-
tion rate (KA), residual unexplained variability (RUV) as
well as diagonal trends for inter-individual variability on
volume (IIV V) and inter-occasion variabilities (IOVs),
evidencing an overestimation of parameter uncertainty and
a misspecification of the symmetry, respectively. The
dOFV distribution of the resamples, i.e., after SIR, was
much improved over that of the proposal and was below
the Chi square distribution (df 9.7). To check whether these
results could be considered final, the temporal trends plot
was inspected: it showed limited downward trends, mostly
within sampling noise. To make sure that M/m had been
sufficient to fully correct the proposal, SIR was performed
with an additional 5000 samples from the covariance
matrix (M/m = 10): the df of the resamples dOFV distri-
bution did not change (df 9.6 vs. 9.7 previously), nor did
parameter CI. SIR results with M = 5000 were thus con-
sidered final. For pefloxacin (Fig. A3 panel a, Online
Resource 4), the dOFV distribution of the proposal was
also above the Chi square distribution (df 14.2 vs. 10). The
spatial trends plot showed an overprediction of the
uncertainty for some parameters (RUV and covariate effect
on clearance CL) and some discrepancy in symmetry (IIV
V and IOV V). The dOFV distribution after resampling
was below the Chi square distribution (df 8) and no trends
were apparent in the temporal trends plot, suggesting that
the chosen M/m of 5 was sufficient. For phenobarbital
(Fig. A3 panel b, Online Resource 4), the dOFV distribu-
tion of the proposal was only slightly above the Chi square
distribution (df 9 vs. 7), showing good adequacy overall.
Diagonal upward trends indicating asymmetry in the true
variance uncertainties were present in the spatial trends
plot. As the dOFV resamples distribution was 0.6 df lower
than the Chi square and the temporal trends plot showed no
trend, SIR results were considered final.
Once SIR settings were proven appropriate, SIR
parameter 95 % CI (using M = 5000 for all models) could
be compared to those obtained from the covariance matrix,
bootstrap and log-likelihood profiling. For moxonidine
(Fig. 3), all methods provided similar 95 % CI for CL and
V. IIV estimates of CL and V were similar across methods
except for log-likelihood profiling, for which upper bounds
were increased. KA and TLAG 95 % CI were similar for
SIR and log-likelihood profiling, narrower than those
obtained with the covariance matrix and displaying asym-
metry. Asymmetry in the uncertainty of absorption
parameters was even more marked when using bootstrap.
Regarding IOVs, SIR, log-likelihood profiling and boot-
strap led to high asymmetry especially for IOV KA.
Uncertainty in RUV was symmetric but narrower with SIR
and log-likelihood profiling than with the covariance
matrix or bootstrap. Similar observations were made with
the pefloxacin and phenobarbital examples (Fig. A4 panel
a, b, Online Resource 5). In terms of runtime the covari-
ance matrix was the fastest method, followed by log-like-
lihood profiling, SIR and finally bootstrap (namely 14 s,
15 min, 1 and 2 h respectively for the moxonidine exam-
ple; relative differences were similar for the other
examples).
Simulation study: comparative coverage
Coverage with SIR was similar to coverage with the
covariance matrix when using the latter as proposal dis-
tribution. SIR results could however be improved when
inflating the proposal distribution (Fig. 4).
In both simulation examples, coverage with the covari-
ance matrix improved with increasing sample size. 95 %
CI often underestimated the true parameter uncertainty.
Most parameters displayed suboptimal coverage at low
sample size; coverage was worse for IIV parameters,
around 0.85 instead of 0.95. Coverage was however satis-
factory at high sample size, except for IIVs in the PD
example which had a coverage of 0.90. SIR results without
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inflation were similar to or slightly improved over the
covariance matrix, but from the diagnostic plots it was
apparent that SIR settings were not fully appropriate. In
most cases, the dOFV distribution of the proposal was
below the Chi square distribution and diagonal trends were
apparent in the temporal trends plots. Based on the inves-
tigations on the SIR workflow presented in the next para-
graph, SIR was performed again using inflations of the
covariance matrix as proposal distributions. Inflation fac-
tors were chosen as the lowest value (starting from 1 and
increasing by steps of 0.5) for which diagnostic plots
looked appropriate. The inflation factor was 3 for datasets
with 20 individuals, 2 for datasets with 50 individuals, and
1.5 for datasets with 200 individuals. SIR coverage was
greatly improved: only IIV CL and IIV ED50 in datasets
with 20 individuals were still statistically suboptimal using
the optimized SIR workflow.
Impact of M/m and proposal distribution on SIR
results
Changes in SIR settings, i.e., the M/m ratio and the pro-
posal distribution, were investigated to better understand
their impact on SIR results so as to give guidance on how
to choose SIR settings. The investigations, based on the
real data examples, showed that the M/m ratio necessary
for SIR results to be considered final was different in the
three investigated examples, and was lower the closer the
proposal distribution was to the Chi square distribution.
The proposal distribution was found to have a profound
impact on SIR results: distributions slightly wider than the
true distribution performed best, while distributions nar-
rower than the true distribution performed badly. The
diagnostic plots were able to distinguish between appro-
priate and inappropriate settings in all cases.
M/m ratio
The optimal M/m ratio was found to be 6 for moxonidine, 4
for pefloxacin and 2 for phenobarbital, as evidenced by the
visual stabilization of the dOFV distributions at M/m = 6,
M/m = 4 and M/m = 2 respectively (Fig. 5). The df was
very stable for ratios above the optimal ratio, with varia-
tions around 0.1–0.2 df.
The correspondence between the visual stabilization of
the dOFV distributions and the numerical stabilization of
RSE and CI bounds, which are the real metrics of interest
for parameter uncertainty, was investigated. It was found
that visually stable dOFV distributions corresponded to
relatively stable RSE and CI bounds, and vice versa. In the
case of moxonidine for example, parameter RSE using an
M/m ratio of 10 instead of 8 changed on average by less
than 1.9 % of their value (range [0.1–5.2 %], see Online
Resource 6). How fast RSE and CI stabilized over
increasing M/m differed greatly between parameters. The
RSE and CI bounds appeared quite stable from the lowest
M/m ratio for CL, V and IIV V, whereas for KA, TLAG,
IIV CL and IOV CL stabilization did not occur until M/
CL V KA TLAG
IIV CL IIV CL−V IIV V IIV KA
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m = 4. Stabilization was slowest for IIV KA and IOV KA,
occurring around M/m = 6.
Proposal distribution
The impact of the proposal distribution was investigated to
see whether SIR would lead to better results when using
modifications of the covariance matrix as proposal distri-
butions. In this work only modifications of the covariance
matrix were investigated, but it is important to stress that
any distribution can be used as proposal distribution for
SIR and that the covariance matrix is thus not required for
SIR to be performed. Figure 6 displays the estimated df of
the SIR dOFV distributions as a function of M/m for dif-
ferent proposal distributions. As expected, the proposal
distributions affected how fast SIR stabilized: higher M/m
ratios were necessary to reach stable dOFV distributions
when starting from inflations of the covariance matrix.
Stabilization of the df was not reached for any of the
models at an M/m ratio of 10 when starting from a twofold
inflation of the covariance matrix, and was also not reached
at M/m = 10 for the 1.5-fold inflation of the moxonidine
covariance matrix. For deflations of the covariance matrix
on the other hand, stabilization seemed faster, even if slow
degrees of freedom increases were visible, in particular for
phenobarbital. However, the diagnostics plots when using
deflated proposal distributions showed trends indicating too
lowM/m ratios in the temporal trends plots. A stable df was
thus not a good indicator of SIR performance when the
proposal distribution was too narrow (i.e., below the Chi
square distribution). Given that the degrees of freedom was
still much lower for the deflations than for the inflations at
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Fig. 4 Coverage with SIR is as
good as or better than coverage
with the covariance matrix. The
squares represent the observed
95 % coverage for the
parameters of the two
simulation examples with SIR
(red) and with the proposal
distribution (blue). The
horizontal error bars represent
the 95 % CI around the
observed coverage (500
simulated datasets per example
and dataset size). SIR was
performed both with the default
workflow (‘‘no inflation’’
panels: covariance matrix as
proposal distribution and M/
m = 5) and with an optimized
workflow (‘‘inflation’’ panels:
covariance matrix inflated by 3,
2 and 1.5 for the datasets with
20, 50 and 200 individuals
respectively as proposal
distributions and M/m = 5)
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M/m = 10, it appeared that too narrow proposal distribu-
tions would need much higher ratios to converge than too
wide proposal distributions. Lastly, the degrees of freedom
obtained with SIR starting from the deflations and infla-
tions of the covariance matrix did not converge at the
highest tested M/m ratio of 10. Differences in df at this
point spanned 5 df for moxonidine, 4 df for pefloxacin and
2 df for phenobarbital.
Discussion
SIR was successfully implemented in the NLMEM
framework and is available as a user-friendly modelling
support tool in the PsN software. SIR was able to
characterize parameter uncertainty more accurately than
conventional methods such as the covariance matrix, the
bootstrap or log-likelihood profiling. A workflow based on
specifically designed diagnostics was proposed to guide the
user on how to perform SIR.
SIR workflow
Based on the performed investigations, the following
decision tree (Fig. 7) is recommended when performing
SIR:
(1) Choose the best guess of the uncertainty distribution.
The covariance matrix can be used if available, but it


































Fig. 5 SIR dOFV distributions converge with increasing number of
initial samples. Comparative dOFV distributions and estimated df for
the covariance matrix as proposal distribution (blue dotted line), SIR
with increasing number of initial samples (colored full lines) and the
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Fig. 6 Degrees of freedom of the SIR dOFV distributions do not
fully converge between inflation factors over increasing number of
samples. Squares represent the df for SIR with increasing inflation
factors (colored full lines) as a function of the number of samples
M for the three real data examples. The horizontal dashed lines
correspond to the number of estimated parameters for each model
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samples, or any other guess of the uncertainty
distribution can be used as proposal distribution.
(2) Perform SIR. The recommended samples/resample
ratio M/m is 5 (for proposal distributions expected to
be close to the true uncertainty, such as the
covariance matrix), but may be increased to 10 for
example (for other, less well informed proposal
distributions).
(3) Check the diagnostics. If the proposal dOFV distri-
bution is below the Chi square distribution (u-shaped
trends will be present in the spatial trends plot),
restart SIR with a wider proposal distribution (for
example using an inflation factor of 1.5). If the
proposal dOFV distribution is above the Chi square
distribution and trends are apparent in the temporal
trends plot, increase M (double for example). If the
proposal dOFV distribution is above the Chi square,
no trends are apparent in the temporal trends plot and
the SIR dOFV distribution is below the Chi square
distribution, SIR results can be considered final.
Real data examples: comparison of SIR with other
methods for parameter uncertainty
Interpretation of differences in parameter 95 % CI between
methods is not straightforward with real data examples as
the true uncertainty remains unknown. Although some case
studies are available [34], thorough comparisons of the
performance of available methods to assess parameter
uncertainty such as in Donaldson et al. [35] for nonlinear
fixed effects models are lacking in NLMEM. In the
investigated real data examples, starting from symmetric
covariance matrix-based uncertainty, SIR was able to pick
up expected asymmetry for given parameters such as
variances and nonlinear processes (Figs. 3, A4, Online
Resource 5). Results were often closest to those obtained
with log-likelihood profiling, which could be expected as
both rely on evaluation of the log-likelihood on the original
dataset. However, contrarily to SIR, uncertainty using log-
likelihood profiling is univariate and cannot be used for
simulation. In addition, log-likelihood profiling requires
reparameterization of the models featuring correlations
between variances, since single matrices elements cannot
be fixed in NONMEM. Bootstrap results also displayed the
presence of asymmetry in the uncertainty distribution of
selected parameters, but bootstrap CI were in general
slightly wider than with SIR. However, bootstrap beha-
viour had been shown to be suboptimal for the considered
real data examples [15]. In addition, in the pefloxacin
example half of the bootstrap samples were unsuccessfully
minimized, further evidencing the complications of this
method to assess parameter uncertainty as the way to
handle failed runs is not standardized and leads to different
results. Contrarily, with SIR the likelihood of the data need
only be evaluated, not estimated, which avoids issues
related to convergence problems. Furthermore, as SIR
evaluates likelihoods over the entire parameter space
defined by the proposal distribution, it might help detecting
if the final estimates were in a local minimum. A warning
is printed if the SIR procedure detects one or more
parameter vector(s) leading to lower OFV than the final
estimates, which can help the user detect local minima.
Both the performance of the default SIR workflow and the
observed differences in 95 % CI between uncertainty
methods in these real data settings are dependent on the
chosen real data examples, which were all PK models
with 1-compartment first order elimination. While further
research is ongoing to identify potential limitations of
SIR, there is little reason to believe that the results
obtained here are not generalizable to other, more com-
plex models.
Regarding runtime, SIR is expected to provide signifi-
cant runtime gains over bootstrap, but quantification of this
gain is not easily generalizable from the investigated
examples. Runtime gains depend on two aspects: the ade-
quacy of the proposal density, which determines the nec-
essary M/m ratio and thus the number of evaluations to
perform, and the difference in runtime between an esti-
mation and an evaluation, which is known to be very
variable depending on the model and data. The more the
proposal distribution is adequate and the more an evalua-
tion is fast compared to an estimation, the greater SIR
runtime gains will be.
3.Check graphical diagnostics 
Proposal dOFV  
≤  χ2
Proposal dOFV > χ2  
 temporal trends 
Proposal > χ2
SIR ≤ χ2 
no temporal trends 
2.Perform SIR 
Recommended samples/resamples ratio: M/m=5000/1000* 
1.Identify proposal 









*for informed proposal distributions such as covariance matrix or limited bootstrap. Could be increased to 
10000/1000 if starting from educated guess for example.
Fig. 7 Decision tree for how to perform SIR in practice. v2 is the Chi
square distribution
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Comparative coverage
In the simulation examples, the coverage with SIR starting
from the covariance matrix was similar to the coverage
with the covariance matrix itself (Fig. 4). However, SIR
outperformed the covariance matrix when starting from an
inflated proposal distribution.
The default workflow did not lead to better results
with SIR than with the covariance matrix in the sim-
ulation examples despite showing improvement in the
real data examples. This was linked to the fact that the
covariance matrix generally underestimated the true
uncertainty in the simulated datasets, whereas it usu-
ally overestimated uncertainty in the real data exam-
ples. As evidenced from the investigation of the
different proposal distributions, SIR is much more
efficient when starting from overestimated proposal
distributions than when starting from underestimated
proposal distributions, which explained why SIR effi-
ciency was reduced for simulations as compared to
real data. The fact that the uncertainty based on the
covariance matrix was suboptimal for some parame-
ters, especially at low samples sizes, was not surpris-
ing. Such behaviour had been previously observed, for
example with simulations with a two-compartment PK
model of a dataset comprising 26 individuals and
rather rich sampling where the 95 % CI did not
include the true simulation value for 7 out of the 12
model parameters [36].
Suboptimal coverage could be corrected for all dataset
sizes when inflations of the covariance matrix were used as
proposal distributions for SIR. As expected, the optimal
inflation factor needed decreased with dataset size, as the
adequacy of the covariance matrix increased. Inflation
factors could be easily determined based on the developed
diagnostics. The same inflation factors could be used for
both simulation examples, thus covariances matrices
seemed to perform similarly for similar numbers of
parameters (5 for the PK example and 6 for the PD
example) in the investigated cases.
It is worth noting that the final SIR dOFV distribu-
tion overlaid the Chi square distribution in the simu-
lation examples. This could indicate that the
stabilization of SIR dOFV distributions below the Chi
square distribution observed in the real data examples
may be due to model misspecification. However, the
proportion of parameters corresponding to random
effects was lower in the simulation examples than in
the real data examples (50–60 vs. 63–80 %). This could
also explain in part why the degrees of freedom of the
SIR dOFV distribution was higher in the simulations
than in the real data examples, as the parameter space
was less restricted.
Performance of SIR diagnostics
The three developed diagnostics (dOFV distribution, spa-
tial trends plot and temporal trends plot, exemplified in
Fig. 2) proved highly relevant to judge whether SIR results
could be considered final, both on a global (all parameters)
and on a local (parameter by parameter) level. They were
able to determine whether SIR settings were appropriate,
i.e., whether M/m was sufficient to correct for the potential
inadequacy of the proposal distribution. SIR results were
correctly identified to be final when two conditions were
fulfilled: the SIR dOFV distribution had to be at or below
the Chi square distribution, with no trends apparent in the
temporal trends plot. The first condition alone was not
sufficient, as shown with deflations of the covariance
matrix for which dOFV distributions were below the Chi
square distribution but trends remained in the temporal
trends plot, leading to too narrow CI. The df was a good
surrogate for the stabilization of the dOFV distribution. It
proved robust towards sampling noise, varying very little
when performing the sampling or the resampling steps
using different seeds (data not shown). More importantly,
stabilization of the dOFV distribution was shown to cor-
relate well with the actual quantities of interest, i.e., the
stabilization of the parameter uncertainty distribution as
summarized by RSE and CI. Marked differences in M/m
ratios needed for stabilization were observed between
parameters, in accordance to the expected appropriateness
of the covariance matrix for the different parameters.
In addition to judging whether SIR settings were
appropriate, the developed diagnostics informed in a
qualitative manner about the adequacy of the proposal
distribution: the smaller the distance between the dOFV
distribution of the proposal and the Chi square distribution,
the greater the adequacy of the proposal distribution.
Spatial trends plots showed that symmetric proposal dis-
tributions often appeared inadequate for variances, pin-
pointing which parameters are typically not well described
by the covariance matrix. This could in theory be used to
refine the proposal distribution parameter by parameter.
This was not attempted here both because performing
changes at the univariate level when working with poten-
tially correlated multivariate distributions is difficult, and
because the correspondence between differences in the
proportion of resamples and needed changes in the pro-
posal distribution was not straightforward.
The evaluation of final SIR results would be much easier
if the true df was known, in which case SIR results could
be considered final as soon as the dOFV distribution would
converge to the corresponding Chi square distribution.
However, factors such as the presence of random effects,
implicit or explicit parameter boundaries (e.g., variances in
the positive domain or physiological boundaries) or model
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misspecification leave the true degrees of freedom in
NLMEM models uncertain. From the experience in this
work, it appears that the true degrees of freedom could
potentially be derived from the convergence of the SIR
dOFV distributions. The degrees of freedom stabilized
around 0.8–0.9 times the total number of estimated
parameters in the considered examples. To investigate
whether this decrease could be linked to constraints in the
parameter space, the proportion of parameter vectors sim-
ulated from the unbounded original covariance matrix that
did not fulfil the constraints was computed. The rejection
rate was below 10 % for the three real data examples.
Whether a metric, such as the rejection rate, could be used
as a correction factor to the expected degrees of freedom of
the SIR resamples dOFV distribution remains to be
explored. Another alternative to estimate the expected
degrees of freedom could be to compute an empirical
dOFV distribution obtained using stochastic simulations
and re-estimations of the model. However, this is both
computationally intensive and disregards the potential
influence of model misspecification, which is why it was
not considered here.
Impact of M/m and proposal distribution on SIR
results
SIR provided satisfactory results when starting from the
covariance matrix with a M/m ratio of 5 in the real data
examples. However, it was important to understand howM/
m is impacted by the adequacy of the proposal distribution
and how SIR would perform when starting from less ade-
quate proposal distributions.
M/m
A ratio of 5 was sufficient when starting SIR from the
covariance matrices of the three relatively simple PK
models investigated, and could have been further reduced
to two and four for two of the models. A quantitative link
between M/m and the adequacy of the proposal distribution
as measured by the df or the difference in df from the Chi
square distribution, could help choosing an appropriate M/
m to perform SIR. Differences in df between proposal
distributions and Chi square distributions were around 2, 4
and 15 df under the initial SIR settings, corresponding to
degrees of freedom 1.3, 1.4 and 2.4-fold higher than the
Chi square degrees of freedom. It thus appeared that
optimal M/m were around twice the ratio between the df of
the proposal distribution and the df of the Chi square dis-
tribution in the investigated examples. However, this
should not be regarded as an established quantitative
relationship between degrees of freedom ratios and optimal
M/m as only a very limited number of cases were
investigated. The developed diagnostics thus enabled to
assess whether M/m was sufficient a posteriori, but no
quantitative relationships between the degrees of freedom
of the proposal distributions and M/m could be established
to inform the SIR procedure a priori.
Proposal distribution
The covariance matrix proved to be a good proposal dis-
tribution in the investigated real data examples. Starting
from too narrow proposal distributions (deflations) proved
problematic for SIR, as the limited number of samples in
the tails of the distribution makes the expansion of
parameter uncertainty very slow. Conversely, the reduction
of parameter uncertainty was much easier, as evidenced by
greater degrees of freedom drops between the different M/
m for wider proposal distributions (Fig. 6). Too narrow
proposal distributions could however be identified by the
developed diagnostics, as they displayed dOFV distribu-
tions below the reference Chi square distribution and
u-shaped trends were present in the spatial trends plots.
After performing SIR with the best guess of parameter
uncertainty, a change in proposal distribution should be
considered instead of a change in M/m for increasing SIR
efficiency in cases for which the proposal dOFV distribu-
tion is below the Chi square distribution and the spatial
trends plot show u-shaped trends (inflate proposal distri-
bution), or if the proposal distribution is way above the Chi
square (deflate proposal distribution).
Even if the investigated proposal distributions were all
derived from the covariance matrix, one major advantage
of SIR is that it can be used even if the covariance matrix is
not available. Any multivariate parametric distribution can
indeed be used as proposal distribution. For example, one
could think of using as proposal distribution the asymptotic
covariance matrix obtained at an earlier stage of model
development, with the uncertainty of all parameters already
present at the earlier stage set to the values of the previous
covariance matrix and the uncertainty of the new param-
eters set to an arbitrary number. Alternatively, an empirical
covariance matrix obtained from a limited number of
bootstrap samples (the minimum number of samples being
the number of estimated parameters so that the matrix is of
full rank), a generalized inverse/Cholesky matrix based on
the R matrix [11] or even an educated guess (for example,
30 % RSE on all parameters and no correlations) could
also be used. How to use such proposal distributions is
detailed in the PsN user guide.
Modifications of the covariance matrix were used to
mimic various types of proposal distributions in this work.
SIR results starting from inflations greater than or equal to
1 had not converged at the highest tested M/m ratio of 10,
which indicated that higher ratios would be needed to
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achieve final SIR results if the proposal distribution is
heavily misspecified (Fig. 6). To reach final results effi-
ciently, modifications of the proposal distribution looked
like a better alternative than increasing M/m: changes in
degrees of freedom were constant and high between pro-
posal distributions (increases of 10, 12 and 28 df per
inflation unit of 1 for pefloxacin, phenobarbital and mox-
onidine respectively) whereas changes in degrees of free-
dom between M/m ratios were low and decreased
drastically with increasing M/m and decreasing inflation
factor (highest changes of 7, 3 and 2 df for twofold inflated
proposal distributions).
Another dimension of the proposal distribution, which
deserves attention but was not investigated in this work,
is the correlation between parameter uncertainty distri-
butions. Just as it is difficult for SIR to compensate for
too narrow proposal distributions, reducing the absolute
value of correlations is much more difficult than
increasing it, as the number of vectors leading to low
correlations will be low when simulated under high
correlations. Correlations were low in all investigated
real data examples and were kept unchanged under
inflations/deflations of the proposal distribution. How-
ever, high correlations are often observed, for example
between maximum effect (Emax) and concentration
leading to half the maximum effect (EC50) in Emax
models. Such correlations may heavily restrict both the
size and the shape of the investigated parameter space.
Causes and consequences of potentially misspecified
correlations are unclear and few examples investigating
this have been published in NLMEM [37]. Reducing
correlations between highly correlated parameter
uncertainties (while increasing the number of initial
samples) should nevertheless be considered when per-
forming SIR to guard against too confining constraints.
More generally, the covariance matrix is known to be a
bad approximation of the true uncertainty in the presence
of high curvature (i.e., non-normal uncertainty, which
happens for example when sample sizes are low, or when
parameters are very nonlinear) or collinearity between
parameters, especially if the correlation is nonlinear
(such as for parameters of the sigmoid Emax model)
[38]. It is thus highly advised to use parameterizations
that minimize such issues, as proposed in Reeve et al.
[8].
At this point it is relevant to mention that the ultimate
diagnostic to test whether SIR results are final would be to
perform SIR using the final SIR results as proposal distri-
bution and see no difference between this proposal distri-
bution and the new SIR results. This thought, i.e. running
iterative SIRs until convergence is reached, is currently
under investigation and is readily available in PsN 4.6.0
(released May 2016).
Conclusion
The SIR method was applied to parameter uncertainty
estimation in NLMEM and diagnostics to assess the
appropriateness of SIR settings were developed. SIR is fast,
does not require parameter estimation or distributional
assumptions, and is thus expected to perform better than
previously available methods for parameter uncertainty
assessment in many cases, including small datasets, highly
nonlinear models or meta-analysis. An implementation of
the SIR method is readily available in the PsN software
package. Further improvements to the SIR workflow,
including iterative SIR procedures and more flexible pro-
posal distributions, are under development.
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